News
Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA PR Newswire
View ArticleNews
U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur's Investigational Clostridium difficile Vaccine Yahoo
View ArticleNews
Sanofi Pasteur Starts a Phase II Vaccine Trial for Primary Prevention of Clostridium Difficile Yahoo
View ArticleNews
Optimer Pharmaceuticals' bacterial infection drug gets 6-month FDA review Yahoo/AP
View ArticleLabeling and Script Use May Cause Problems For Optimer's New Drug
Labeling and Script Use May Cause Problems For Optimer's New Drug Seeking Alpha
View ArticleFDA Approves Optimer's DIFICID (fidaxomicin) Tablets for the Treatment of...
FDA Approves Optimer's DIFICID (fidaxomicin) Tablets for the Treatment of Patients with Clostridium difficile-Associated Diarrhea (CDAD) Yahoo/PR NewsWire
View ArticleOptimer climbs in pre-market trading and company readies launch of first...
Optimer climbs in pre-market trading and company readies launch of first FDA-approved drug Yahoo/AP
View ArticleOptimer Prices New Antibiotic at Premium
Optimer Prices New Antibiotic at Premium TheStreet.com
View ArticleCubist might stay clear of Ph3 for antibiotic, analyst says
Cubist might stay clear of Ph3 for antibiotic, analyst says Fierce Biotech
View ArticleCHMP Recommends Astellas Pharma Europe Ltd.'s (APEL) DIFICLIR for Approval in...
CHMP Recommends Astellas Pharma Europe Ltd.'s (APEL) DIFICLIR for Approval in the EU Yahoo/PR NewsWire
View ArticleCubist plans late-stage studies of diarrhea drug
Cubist plans late-stage studies of diarrhea drug Yahoo/AP
View ArticleOptimer's DIFICID provides economic value in the treatment of CDAD
Optimer's DIFICID provides economic value in the treatment of CDAD Yahoo/Fly on the Wall
View ArticleFDA says ulcer drugs may raise diarrhea risk
FDA says ulcer drugs may raise diarrhea risk Reuters
View ArticleNew Data Demonstrates DIFICLIR™ May Offer Benefits for Cancer Patients, who...
New Data Demonstrates DIFICLIR™ May Offer Benefits for Cancer Patients, who are at High Risk of Clostridium Difficile Infection Sacramento Bee, CA
View Article
